- Total Equity Funding
- $49.29M in 2 Rounds from 11 Investors
- Most Recent Funding
- $41M Series B on January 4, 2017
- Redwood City, California
- Synthego is a provider of synthetic RNA solutions for CRISPR Genome Engineering.
- Alex Pesch, Michael Dabrowski, Paul Dabrowski
- Genetics, Biotechnology, Software, Innovation Management, Industrial Automation
Founded by former SpaceX engineers, Synthego is a leading provider of genome engineering solutions. The company's flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research.
Synthego's vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
Headquartered in Silicon Valley, California, Synthego customers include leading institutions in over 30 countries around the world and 9 of the top 10 global biology universities.
Funding Rounds (3) - $49.54MUpdate
Current Team (4)Update
|May 16, 2017||TechCrunch - Synthego’s genetic toolkit aims to make CRISPR more accessible|
|Apr 20, 2017||TechCrunch - Announcing the TechCrunch Disrupt NY 2017 agenda|
|Mar 17, 2017||Venture Capital Database - The CRISPR Economy: 7 Private Startups Pursuing The New Frontier In Biotech|
|Mar 2, 2017||TechCrunch - How Synthego’s founders went from a mission to Mars to a mission to cure disease|
|Jan 4, 2017||New York Times (NYT) - Synthego Raises $41 Million From Investors, Including a Top Biochemist|
|Aug 12, 2013||SEC - SEC FORM D|
|Jul 8, 2013||Boston Tech Flash - Synthego raises 8294226 in venture round|
3696 Haven Avenue Suite A
Redwood City, California 94063
Redwood City, California